Education
About Us
Working with TipRanks
Follow Us
HilleVax, Inc (HLVX)
:HLVX
HLVX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.34 - $15.60
Previous CloseN/A
Volume43.09K
Average Volume (3M)236.31K
Market Cap
$98.28M
Enterprise ValueN/A
Total Cash (Recent Filing)$189.31M
Total Debt (Recent Filing)$24.97M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Aug 07, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding50,141,064
10 Day Avg. Volume115,845
30 Day Avg. Volume236,312
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.43
Price to Sales (P/S)0.00
P/FCF Ratio-0.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.00Price Target Upside2.04% Upside
Rating ConsensusHold
Number of Analyst Covering2
HilleVax, Inc News
PremiumCompany Announcements
HilleVax Reports Improved Financial Performance
PremiumCompany Announcements
HilleVax Reports 2024 Financial Results Amid Strategic Exploration
PremiumPre-Earnings
Is HLVX a Buy, Before Earnings?
PremiumCompany Announcements
HilleVax, Inc. Announces Workforce Reduction and Leadership Changes
PremiumCompany Announcements
HilleVax Reports Q3 Financial Results Amid Strategic Planning
Bulls Say, Bears Say
Bulls Say
Financial PositionThe company has approximately $159.5 million in cash and equivalents and has made significant reductions in operating expenses, positioning it to streamline its platform for future steps.
Future OpportunitiesThe norovirus opportunity remains tangible, with the potential to prevent moderate-to-severe acute gastroenteritis caused by norovirus infection, which results in significant global deaths annually.
Strategic DevelopmentThere is consideration of strategic alternatives and business development activities, including a focus on broader pipeline prospects.
Bears Say
Clinical Trial ResultsThe Phase 2B NEST-IN1 trial for the HIL-214 vaccine did not achieve its primary or secondary endpoints, leading to the discontinuation of its development for infant patients.
Operational ExpensesHLVX reported 4Q OpEx of $36.1M which was +112% vs. our $17M.
Uncertainty In DevelopmentNear-term uncertainty exists as the company explores paths forward for its norovirus vaccine development.
Options Prices
Currently, No data available
---
Ownership Overview
3.88% Insiders
5.60% Mutual Funds
61.14% Other Institutional Investors
21.70% Public Companies and
Individual Investors
HLVX FAQ
What was HilleVax, Inc’s price range in the past 12 months?
HilleVax, Inc lowest stock price was $1.34 and its highest was $15.60 in the past 12 months.
What is HilleVax, Inc’s market cap?
HilleVax, Inc’s market cap is $98.28M.
When is HilleVax, Inc’s upcoming earnings report date?
HilleVax, Inc’s upcoming earnings report date is Aug 07, 2025 which is in 62 days.
How were HilleVax, Inc’s earnings last quarter?
HilleVax, Inc released its earnings results on May 08, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.365 by $0.245.
Is HilleVax, Inc overvalued?
According to Wall Street analysts HilleVax, Inc’s price is currently Undervalued.
Does HilleVax, Inc pay dividends?
HilleVax, Inc does not currently pay dividends.
What is HilleVax, Inc’s EPS estimate?
HilleVax, Inc’s EPS estimate is -0.14.
How many shares outstanding does HilleVax, Inc have?
HilleVax, Inc has 50,141,064 shares outstanding.
What happened to HilleVax, Inc’s price movement after its last earnings report?
HilleVax, Inc reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.365. Following the earnings report the stock price went up 3.243%.
Which hedge fund is a major shareholder of HilleVax, Inc?
Currently, no hedge funds are holding shares in HLVX
HilleVax, Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (2.04% Upside)
$2.00 (2.04% Upside)
Insider Transactions
Sold Shares
Worth $63.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-85.62%
12-Months-Change
Fundamentals
Return on Equity
-54.64%
Trailing 12-Months
Asset Growth
-43.08%
Trailing 12-Months
Company Description
HilleVax, Inc
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
HLVX Stock 12 Month Forecast
Average Price Target
$2.00
▲(2.04%Upside)